Most Read Articles
Yesterday
Administering intranasal desmopressin to patients with renal dysfunction not requiring haemodialysis reduces bleeding complications during renal biopsies, especially minor complications such as perinephric haematomas, a study has found. However, it may increase the risk of incident hyponatraemia.
Pearl Toh, 10 Oct 2019
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
3 days ago
Environmental quality and exposure to pollution may play a small part in the development of metabolic diseases, such as diabetes, a new study has found.
Tristan Manalac, 5 days ago
Sleep deprivation impairs adolescents’ long-term retention of classroom material, according to a recent Singapore study.

Orvepitant delivers sustained improvements in chronic refractory cough

18 Sep 2019

Treatment with the neurokinin-1 receptor antagonist orvepitant appears to be safe in patients with chronic refractory cough, yielding sustained improvements in cough frequency and severity, according to the results of the phase II VOLCANO-1 trial.

Thirteen patients with daytime cough frequency of >3 to <250 coughs/hour received orvepitant 30 mg once daily for 4 weeks. Objective cough frequency was measured over 24 hours at several time points: baseline and weeks 1, 4, and 8.

The primary outcome was change in daytime cough frequency at week 4. Secondary outcomes included cough severity score on visual analogue scale (VAS), global ratings of change for cough frequency and severity, and Cough-specific Quality of Life Questionnaire score.

Mean objective daytime cough frequency at baseline was 71.4/hour. This improved by 26 percent at week 4, translating to a decrease of 18.9 coughs/hour (95 percent CI, 9.6–28.3; p<0.001).

The improvement was already evident during the first week of treatment (reduction from baseline of 38 percent or 27.0 coughs/hour, 11.4–42.7; p=0.001) and sustained after drug discontinuation through week 8 (reduction of 29 percent or 20.4 coughs/hour, 3.2–37.5; p=0.020). There were significant, parallel improvements seen in severity VAS and quality of life scores.

These findings show that orvepitant merits further clinical investigation, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Administering intranasal desmopressin to patients with renal dysfunction not requiring haemodialysis reduces bleeding complications during renal biopsies, especially minor complications such as perinephric haematomas, a study has found. However, it may increase the risk of incident hyponatraemia.
Pearl Toh, 10 Oct 2019
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
3 days ago
Environmental quality and exposure to pollution may play a small part in the development of metabolic diseases, such as diabetes, a new study has found.
Tristan Manalac, 5 days ago
Sleep deprivation impairs adolescents’ long-term retention of classroom material, according to a recent Singapore study.